Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 02/25/25
Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated CatalystsGlobeNewsWire • 02/25/25
Wall Street Analysts See a 67.27% Upside in Beam Therapeutics (BEAM): Can the Stock Really Move This High?Zacks Investment Research • 02/13/25
Is Beam Therapeutics (BEAM) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 02/10/25
Wall Street Analysts Think Beam Therapeutics (BEAM) Could Surge 84.45%: Read This Before Placing a BetZacks Investment Research • 01/28/25
Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTRGlobeNewsWire • 01/23/25
Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated CatalystsGlobeNewsWire • 01/13/25
Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 12/08/24
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 12/07/24
Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial OfficerGlobeNewsWire • 12/06/24
Why Is Beam Therapeutics (BEAM) Down 2.3% Since Last Earnings Report?Zacks Investment Research • 12/05/24
Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial LeaderGlobeNewsWire • 12/04/24
Beam Therapeutics to Participate in 2024 Jefferies London Healthcare ConferenceGlobeNewsWire • 11/12/24
Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A WatchSeeking Alpha • 11/07/24
Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 11/05/24